Gradalis, Inc.
DALLAS, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Gradalis Inc. announced a peer-reviewed publication today in the Nature portfolio journal, Communications Medicine, in which several biomarkers were evaluated for their potential to predict survival following Vigil (Gemogenovatucel-T) treatment. The publication entitled ENTPD1 as a Predictive Marker of Treatment Response to Gemogenovatucel-T as Maintenance Therapy in Newly Diagnosed Ovarian Cancer, features results from VITAL, a Phase 2b randomized, double-blind, placebo-controlled trial of Vigil in patients with newly diagnosed ovarian cancer. The analysis indicates that pretreatment expression levels of the ENTPD1 gene may be a significant predictor of overall survival (OS) and recurrence-free survival (RFS) following Vigil therapy. Vigil is a novel, personalized cellular immunotherapy platform that is designed to decloak the full repertoire of a patients tumor antigens, reactivate the immune system, and summon key effector cells to deliver a durable clinical response. In VITAL, Vigil showed a positive trend in RFS in the overall population and a significant improvement in RFS and OS in newly diagnosed ovarian cancer patients with BRCAwt and HRP molecular profiles. This finding may allow for a more refined targeting of patients who will benefit from Vigil therapy.
The ENTPD1 gene, also referred to as CD39, is a protein coding gene that functions as a limiting step in the adenosine metabolic pathway found in immunosuppressive tumor microenvironments. ENTPD1 gene directed signaling is involved in a wide range of cancers.In the analysis, a high level of RNA expression by the ENTPD1 gene (High ENTPD1) was prospectively defined as greater than the median value, hence representing 50% of patients. High ENTPD1 was associated with improved RFS and OS following Vigil maintenance treatment in frontline ovarian cancer patients. The analysis was conducted in collaboration with the University of South Alabama.
Story continues
While the use of predictive biomarkers to identify populations most likely to benefit from immunotherapy has expanded and evolved, attempts to use this approach in the treatment of ovarian cancer have thus far been underwhelming, said Rodney Rocconi, M.D., Professor, Obstetrics and Gynecology at University of Alabama at Birmingham and study investigator. The Phase 2b VITAL trial demonstrated statistically significant improvement in RFS and OS when Vigil was used as a frontline maintenance therapy in patients with BRCAwt as well as HRP subtype advanced ovarian cancer. These exciting data and the identification of ENTPD1 as a biomarker that is predictive of response to Vigil, independent of BRCAwt and HRP status, represent a promising step forward with the potential to provide meaningful benefits for ovarian cancer patients.
The full text of the article can be found here: https://www.nature.com/articles/s43856-022-00163-y. Key findings in the paper include:
High ENTPD1 expression predicts response to Vigil versus placebo regardless of HR status: At 40 months elapsed, median RFS was not yet reached in the Vigil treated group (n=23) vs. 8.1 months in the placebo group (n=23), p=0.00007; at 40 months elapsed, median OS was not yet reached in the Vigil treated group vs. 41.4 months in the placebo group, p=0.013.
High ENTPD1 expression with HRP status: RFS and OS were further improved in Vigil patients with tumors demonstrating High ENTPD1 and HRP status compared to the placebo group. Median RFS of 21.1 months was observed in the Vigil treated group (n=11) vs. 5.6 months in the placebo group (n=9), HR=0.18, p=0.004; at 40 months elapsed, median OS was not yet reached in the Vigil treated group vs. 27 months in the placebo group, HR=0.23, p=0.025.
John Nemunaitis, M.D., Chief Scientific Officer of Gradalis commented, ENTPD1 is recognized to be an important gene in cancer development and progression. ENTPD1 has been identified as playing a role in numerous other solid tumor indications, including melanoma, lung cancer and colorectal cancer. There has been growing interest and support from large pharmaceutical companies for the development of drugs targeting the ENTPD1/CD39 axis. The findings published today further underscore the clinical utility of biomarker approaches to predict survival differences across BRCAwt and HRP positive ovarian cancer patients treated with Vigil. We plan to further validate these findings in the Vigil registrational program and hope to use such a biomarker-based patient selection strategy to expand the potential of Vigil across a variety of cancers.
Mr. Steven Engle, Chief Executive Officer of Gradalis added, In 2003, Gradalis founders including our CSO, Dr. Nemunaitis, had the foresight to explore more effective solutions to treat cancer, including approaches that leveraged the patients immune system to target the entire tumor. Based on multiple clinical studies, Gradalis has developed Vigil, an oncology treatment that is designed to decloak the full repertoire of a patients tumor antigens, reactivate the immune system, and summon key effector cells to deliver a durable clinical response. When combined, this powerful trifecta of anti-cancer activity has the potential to eliminate elusive metastatic cells and thus improve survival, as shown in our Phase 2 clinical studies in ovarian cancer.
Mr. Engle continued, Importantly, Vigil activates the patients immune system without disrupting its natural state of balance. As a result, multiple clinical trials have demonstrated that Vigil is well tolerated and has an encouraging safety profile compared to currently approved standard of care treatment options. Taken together, we believe Vigil has the potential to become a game-changing therapeutic approach in oncology. If validated in a planned Phase 3 trial, the ENTPD1 finding may be applicable to multiple cancer tumor types, providing the potential to explore new opportunities to maximize the therapeutic benefit of Vigil.
About Ovarian Cancer and Molecular ProfilesEvery year, an estimated 22,000 patients are diagnosed with ovarian cancer in the U.S. and 14,000 patients die. The biomarker analysis in the VITAL Phase 2b trial focused on patients with ovarian cancer who had the BRCA wildtype (BRCAwt) gene and whose tumors had the homologous recombination proficient (HRP) molecular profile. Patients with the BRCAwt molecular profile have less than a 35% chance of surviving ovarian cancer at five years following diagnosis. BRCAwt is found in over 75% of patients with ovarian cancer and in 90% or more of several other tumor types. Patients with the HRP molecular profile have less than a 30% chance of surviving ovarian cancer at five years following diagnosis. HRP is found in over 40% of patients with ovarian cancer and in 80% or more of several other tumor types, including skin, colorectal and cervical cancers.
BRCA genesproduceproteinsthat help repair damaged DNA and are sometimes calledtumor suppressor genes. There are two types of BRCA genes: BRCA wildtype (BRCAwt) and BRCA mutated (BRCAmt) gene. In tumors of patients with the BRCAwt gene, mutations that lead to the generation of novel neoantigens on the cell membrane of each cell are less likely to occur. As a result, it is easier for the immune system to identify and target the tumor cells. In patients with the BRCAmt gene, mutations are more likely to lead to the generation of different neoantigens on the cell membrane of each new tumor cell making it more difficult for the immune system to identify and target the tumor cells. Vigil uses the patients immune system to target the tumor, so it is not surprising that Vigil would work better in patients with the BRCAwt gene. Similarly, tumors with the HRP molecular profile are more likely to maintain intact DNA repair pathways, and therefore are also more likely to respond to Vigil therapy.
About VigilVigil is a novel, plasmid engineered, autologous tumor cell immunotherapy platform designed to achieve a trifecta of immune anticancer activity using a unique bi-shRNA DNA based technology and the patients own tumor tissue. The trifecta of systemic activity involves knock down of TGF1 and TGF2 which function as tumor suppressor cytokines, increased GM-CSF expression to enhance local immune function and presentation of the patients clonal neoantigen epitopes via use of autologous cancer tissue. By utilizing the patient's own tumor as the antigen source, Vigil is designed to elicit an immune response that is specifically targeted and broadly relevant to each patient's unique clonal tumor neoantigens. Vigil therapy has been well tolerated in Phase 1, 2a and 2b clinical studies.
In VITAL, a multicenter, randomized, double-blind, placebo-controlled Phase 2b trial (NCT02346747), Vigil showed a positive trend in the primary endpoint of recurrence free survival (RFS) in the overall population and a statistically significant improvement in RFS and overall survival (OS), with a median time of three years to date, in a pre-planned subgroup analysis of Stage III/IV newly diagnosed ovarian cancer patients with the BRCAwt molecular profile. In patients with tumors of the HRP type, significant additional improvement was seen in RFS and OS.
Additionally, Phase 1 results in an all-comer clinical trial have shown positive signals of activity in 19 tumor types and some patients treated with Vigil remain in the trial 48 months later. The company is preparing to initiate a clinical trial intended for product registration in patients with the HRP subtype ovarian cancer.
About Gradalis, Inc.Founded in 2003, Gradalis is a privately held, late-stage clinical biotechnology company developing a personalized immunotherapy called Vigil, that has been tested in multiple studies in ovarian and other cancer tumor types. Based on its Phase 2b clinical trial results, the company is preparing to initiate a Phase 3 trial intended for product registration of Vigil in patients with ovarian cancer. Vigil is the first cellular immunotherapy to demonstrate survival benefits in a randomized controlled trial of patients with solid tumors. The results of the companys Phase 2b trial have been published in Lancet Oncology and presented at the American Society of Clinical Oncology. Vigil is being studied in other womens cancer types and has shown positive results in combination with checkpoint inhibitors
Gradalis Vigil platform uses the patients immune system to target the entire tumor. Based on multiple clinical studies, Gradalis has developed an oncology platform that is designed to decloak the full repertoire of a patients tumor antigens, reactivate the immune system, and summon key effector cells to deliver a durable clinical response. When combined, these are a powerful Trifecta of anti-cancer activities, potentially eliminating even the elusive metastatic cells, and as shown in Phase 2 clinical studies in ovarian cancer, a potential gamechanger in oncology. Our clinical trials have also demonstrated that Gradalis platform is better tolerated compared to standard cancer treatments since Vigil uses the patients immune system operating within its natural state of balance rather than in an artificial overdrive as with some technologies. Vigil utilizes proprietary bi-shRNA technology that has been proven to silence multiple genes in a variety of cancers and has the potential to be used in other diseases.
Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements regarding the success, cost, and timing of our product development activities and clinical trials, our plans to research, develop, and commercialize our product candidates, and our plans to submit regulatory filings and obtain regulatory approval of our product candidates. These forward-looking statements are based on Gradalis current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements include but are not limited to: (a) the timing, costs, and outcomes of our clinical trials and preclinical studies, (b) the timing and likelihood of regulatory filings and approvals for our product candidates, and (c) the potential market size for our product candidates. These forward-looking statements speak only as of the date made and, other than as required by law, we undertake no obligation to publicly update or revise any forward-looking statements. This press release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities.
Gradalis ContactMark Early(214) 442-8161mearly@gradalisinc.com
LifeSci Advisors ContactJoyce Allaire+1 (617) 435-6602jallaire@lifesciadvisors.com
See the original post:
Gradalis Announces Publication in Nature Communications Medicine Identifying Survival Predicting Biomarker in Patients with Ovarian Cancer Treated...
- Exercise promotes a molecular profile in muscle: Research - January 21st, 2023
- Molecular Diagnostics Laboratory < Laboratory Medicine - January 4th, 2023
- Molecular cloning - Wikipedia - December 18th, 2022
- Trends in Molecular Medicine | Journal - ScienceDirect - December 10th, 2022
- Researchers from Insilico Medicine, University of Copenhagen, and University of Chicago unravel molecular secrets hidden in premature aging diseases... - December 2nd, 2022
- Nuclear Medicine and Molecular Imaging Week: October 2-8, 2022 - October 29th, 2022
- Biochemistry & Molecular Biology | Medicine - October 29th, 2022
- Cellular and Molecular Medicine | Faculty of Medicine - October 21st, 2022
- Molecular Diagnostics > Fact Sheets > Yale Medicine - October 21st, 2022
- Expert Reviews in Molecular Medicine | Cambridge Core - October 13th, 2022
- UT Southwestern ranked top health care institution globally for published research by Nature Index - UT Southwestern - October 13th, 2022
- Common Antibiotics Are Losing Their Potency. Researchers Pinpoint Mechanism to Restore It. - NYU Langone Health - October 13th, 2022
- expert reaction to study looking at integrating human stem cell-derived brain-like tissue in the brains of newborn rats - Science Media Centre - October 13th, 2022
- HTG Provides Update on Third Quarter Progress Toward Its Transcriptome-Informed Approach to Drug Discovery - Yahoo Finance - October 13th, 2022
- UVA Discovers Key Driver of High Blood Pressure - UVA Health Newsroom - October 13th, 2022
- Postdoctoral Fellow in Lung Cancer Genomics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311727 - Times Higher Education - October 13th, 2022
- Common cold may increase the risk of long Covid - Earth.com - October 13th, 2022
- Caris' Precision Oncology Alliance Welcomes The Cancer Institute at The University of Tennessee Medical Center - PR Newswire - October 13th, 2022
- Merus Announces Publication of Abstract on MCLA-129 at the 34th EORTC/NCI/AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics - Yahoo... - October 13th, 2022
- Molecular Test Could Improve Early Detection of Pancreatic Cancer - Technology Networks - October 13th, 2022
- UTSW researchers identify key player in cellular response to stress - EurekAlert - October 4th, 2022
- New Antibody Demonstrates Therapeutic Benefits Against Alzheimers - SciTechDaily - October 4th, 2022
- Mount Sinai study uncovers mechanisms of reactive oxygen species in stem cell function and inflammation prevention - EurekAlert - October 4th, 2022
- NovoPath Pushes the Limits of Laboratory Information Systems with Integrated Workflows for Genetic and Molecular Testing - PR Newswire - October 4th, 2022
- Postdoctoral Fellow in Bioinformatics job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 311073 - Times Higher Education - October 4th, 2022
- Breast Cancer Awareness | Nick Jacobs | An unlikely partnership: The United States Army Space and Missile Defense Command and the Joyce Murtha Breast... - October 4th, 2022
- Tackling resistance to HIF2 drugs with an RNA-based therapy - UT Southwestern - October 4th, 2022
- OncoNano Medicine Announces Positive Phase 2 Data for Pegsitacianine as an adjunct to Cytoreductive Surgery of Peritoneal Carcinomatosis - Business... - October 4th, 2022
- SIMATS organizes Induction Ceremony - Afternoonnews - Afternoon News - October 4th, 2022
- ExPath Grad Student Madeline Mayday Awarded Grant from the NIDDK Cooperative Centers of Excellence in Hematology - Yale School of Medicine - September 25th, 2022
- Blood Cancer Discovery Publication Further Validates Exscientia's AI Precision Medicine Platform for Improving Patient Outcomes - Business Wire - September 25th, 2022
- New Startups Built From UC Davis Innovations Drive Solutions in Food, Health and Agriculture - University of California, Davis - September 25th, 2022
- Scientists Discover New Cancer Treatment - The Morning News - September 25th, 2022
- Rewriting the Textbook for Precision Medicine - Technology Networks - September 25th, 2022
- Biden says 'The pandemic is over,' but health experts disagree - Chief Healthcare Executive - September 25th, 2022
- Discovery Illuminates How Parkinson's Disease Spreads in The Brain - Weill Cornell Medicine Newsroom - September 25th, 2022
- AI Used to Determine Cause of Alzheimer's and Related Disorders - Inside Precision Medicine - September 25th, 2022
- Looking Ahead in the Treatment of Breast Cancer - Targeted Oncology - September 25th, 2022
- Researchers identify potential biomarker to distinguish two aggressive types of brain tumors in children - EurekAlert - September 25th, 2022
- New study reveals breakthrough infections increase immunity to COVID-19 - OHSU News - September 25th, 2022
- Coronavirus Today: Who's dying of COVID-19 now? - Los Angeles Times - September 25th, 2022
- Hoag Named Radiopharmaceutical Therapy Center of Excellence, Publishes Results of Breast and Prostate Cancer Trials - PR Newswire - September 8th, 2022
- Orbital Therapeutics Launches to Advance New Frontiers of Science with the Next Generation of Innovative RNA Medicines - Yahoo Finance - September 8th, 2022
- Scientists urged the Biden administration to launch an Operation Warp Speed to develop inhaled COVID vaccines. China beat the U.S. to the punch -... - September 8th, 2022
- Foundation Medicine to Share 14 Abstracts at the 2022 European Society for Medical Oncology (ESMO) Congress Demonstrating the Power of Genomic... - September 8th, 2022
- Monte Rosa Therapeutics Announces FDA Clearance of Investigational New Drug Application for MRT-2359, a GSPT1-directed Molecular Glue Degrader Phase... - September 8th, 2022
- Biden administration says the once-a-year shot phase of the COVID-19 pandemic has arrived - The Boston Globe - September 8th, 2022
- ICCBS welcomes students of MPhil and PhD Programs 2022 - The Academia Mag - September 8th, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 308114 - Times... - September 8th, 2022
- Congratulations to our NRF award winners | UCT News - University of Cape Town News - September 8th, 2022
- Patients with some forms of aggressive esophageal cancers may benefit from treatment targeting how cells self-regulate - EurekAlert - September 8th, 2022
- Molecular Medicine (M.Sc.) - Georg-August-Universitt Gttingen - August 30th, 2022
- Feinstein Institutes Get $3M From Lupus Research Alliance to Study Remission and Future Therapies - Business Wire - August 30th, 2022
- Unlocking the Power of Precision Medicine the Rheumatology Example - Technology Networks - August 30th, 2022
- When to trust your covid test results and when to question them | Mint - Mint - August 30th, 2022
- Molecular Diagnostics Market Report 2022-2030: Increasing Adoption of Point-Of-Care (Poc) Testing and the Development of Novel Assays Presents... - August 30th, 2022
- Advancing Precision Oncology, Ochsner Health First to Fully Integrate with Tempus and Epic's Genomics Module - Newswise - August 30th, 2022
- Tiny, Touch-Based Sensor Could Help Patients Stay on Top of Their Medications - SciTechDaily - August 30th, 2022
- Stellar Scholars Join CLAS Faculty - UConn Today - University of Connecticut - August 30th, 2022
- COVID-19 gave new urgency to the science of restoring smell - Science News Magazine - August 30th, 2022
- Dr. Sun lab wins R01 from National Institutes of Health to study liver proteins - Wayne State University - August 22nd, 2022
- Pasithea Therapeutics to Present Results of Tolerizing Vaccine Program at Prestigious International Immunotherapy Conference - GlobeNewswire - August 22nd, 2022
- New Study Identifies How A Group Of Genes Are Linked To Behavioral Conditions - Forbes - August 22nd, 2022
- New gene variant that protects against coronary heart disease uncovered - EurekAlert - August 22nd, 2022
- How a Japanese Herbal Medicine Protects the Gut Against Inflammatory Bowel Disease - Neuroscience News - August 22nd, 2022
- Insilico Medicine presents on AI for drug discovery at 9th Annual Aging Research and Drug Discovery Conference - EurekAlert - August 22nd, 2022
- Why polio is back on the radar of Canadian health officials - Brighter World - August 22nd, 2022
- Angela DeMichele, MD, MSCE, Assesses the Value of I-SPY2 for Neoadjuvant Treatment of Early Breast Cancer - Cancer Network - August 22nd, 2022
- Exciting PhD positions at the European Molecular Biology Laboratory (EMBL) job with EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) | 304753 - Times... - August 22nd, 2022
- Sensor could help patients stay on top of their meds - EurekAlert - August 22nd, 2022
- Trivitron Healthcare launches CoE in metabolomics, genomics, newborn screening and molecular diagnostics - Express Healthcare - August 22nd, 2022
- Research Trends of Moxibustion Therapy for Pain Treatment Over the Pas | JPR - Dove Medical Press - August 22nd, 2022
- Edited Transcript of EXAI.OQ earnings conference call or presentation 18-Aug-22 12:30pm GMT - Yahoo Finance - August 22nd, 2022
- Roche launches COVID-19 test that detects and differentiates the emerging variant of interest BA.2.75 - PR Newswire - August 22nd, 2022
- Will Omicron BA.5 Be the Last of the COVID Variants? - The Epoch Times - August 22nd, 2022
- Many Paths to Failure | Harvard Medical School - Harvard Medical School - August 5th, 2022
- Mitochondrial DNA Mutations Linked to Heart Disease Risk - University of California San Diego - August 5th, 2022
- UC Davis Sets a New Record, Surpasses $1 Billion in Research Funding - University of California, Davis - August 5th, 2022
- A first update on mapping the human genetic architecture of COVID-19 - Nature.com - August 5th, 2022
- Summer Scholars leave Duke with a once-in-a-lifetime research experience - Duke University - August 5th, 2022